Challenges for the Sustainability of University-Run Biobanks.

Most university biobanks begin like other university research projects, that is, with an idea conceived by an individual researcher in pursuit of his/her own research interests, publications, funding, and career. Some biobanks, however, come to have scientific value that goes beyond the projects that were initially responsible for the collection of the samples and data they contain. Such value may derive from among other things the uniqueness of the samples in terms of their sheer volume, the quality of the samples, the ability to link the samples with information retrieved in disease registries, or the fact that the samples represent very rare diseases. This article focuses on biobanks of this kind, and the special obligations that publicly funded universities have to ensure the sustainability of biobanks with continued scientific value. We argue that universities should adopt policies to deal with the various, diverse issues which may arise during the lifecycle of a biobank. The policies should be flexible, accommodate the freedoms of individual researchers, and reflect the multifaceted nature of biobanks. Yet they should be specific enough to provide guidance and robust enough to safeguard legal norms and ethical values. The article sets out concrete recommendations which universities should consider and act upon.

[1]  J. Lassen,et al.  “I didn’t have anything to decide, I wanted to help my kids”—An interview-based study of consent procedures for sampling human biological material for genetic research in rural Pakistan , 2018, AJOB empirical bioethics.

[2]  Yvonne DeSouza,et al.  The 2018 Revision of the ISBER Best Practices: Summary of Changes and the Editorial Team's Development Process , 2018, Biopreservation and biobanking.

[3]  Thomas Erslev A brain worth keeping? Waste, value and time in contemporary brain banking. , 2017, Studies in history and philosophy of biological and biomedical sciences.

[4]  Jacob S. Sherkow,et al.  Patent protection for CRISPR: an ELSI review , 2017, Journal of law and the biosciences.

[5]  Anders E. Halager,et al.  Sequencing and de novo assembly of 150 genomes from Denmark as a population reference , 2017, Nature.

[6]  Klaus Hoeyer,et al.  Ethics Policies and Ethics Work in Cross-national Genetic Research and Data Sharing , 2017 .

[7]  A. Tupasela Populations as brands in medical research: placing genes on the global genetic atlas , 2017 .

[8]  N. Rajam Biobank-related research and intellectual property rights: deconstructing the obscurity , 2017 .

[9]  S. M. Kelly,et al.  Methods to Improve Sustainability of a Large Academic Biorepository. , 2017, Biopreservation and biobanking.

[10]  M. Henderson,et al.  Achieving and Maintaining Sustainability in Biobanking Through Business Planning, Marketing, and Access. , 2017, Biopreservation and biobanking.

[11]  K. McCluskey A Review of Living Collections with Special Emphasis on Sustainability and Its Impact on Research Across Multiple Disciplines , 2017, Biopreservation and biobanking.

[12]  Jacob S. Sherkow,et al.  The rise of the ethical license , 2017, Nature Biotechnology.

[13]  P. Holub,et al.  BBMRI-ERIC Directory: 515 Biobanks with Over 60 Million Biological Samples , 2016, Biopreservation and biobanking.

[14]  S. Fullerton,et al.  Has the biobank bubble burst? Withstanding the challenges for sustainable biobanking in the digital era , 2016, BMC Medical Ethics.

[15]  Jacob S. Sherkow CRISPR: Pursuit of profit poisons collaboration , 2016, Nature.

[16]  Jacob S. Sherkow Pursuit of Profit Poisons Collaboration , 2016 .

[17]  Daniel Catchpoole,et al.  ‘Biohoarding’: treasures not seen, stories not told , 2016, Journal of health services research & policy.

[18]  Erik Schultes,et al.  The FAIR Guiding Principles for scientific data management and stewardship , 2016, Scientific Data.

[19]  I. Cockburn,et al.  The Economics of Reproducibility in Preclinical Research , 2015, PLoS biology.

[20]  Jens Schovsbo,et al.  Legal aspects of biobanking as key issues for personalized medicine and translational exploitation. , 2014, Personalized medicine.

[21]  Megan Scudellari,et al.  Biobank managers bemoan underuse of collected samples , 2013, Nature Medicine.

[22]  C. V. van El,et al.  The Politics of Representation in the Governance of Emergent 'Secondary Use' Biobanks: The Case of Dried Blood Spot Cards in the Netherlands , 2012 .

[23]  G. Zielhuis Biobanking for epidemiology. , 2012, Public health.

[24]  J. Kaye Governing biobanks: understanding the interplay between law and practice , 2012 .

[25]  B. Keogh European biobanks forge cross-border ties. , 2011, Journal of the National Cancer Institute.

[26]  Michelle M Mello,et al.  The Havasupai Indian tribe case--lessons for research involving stored biologic samples. , 2010, The New England journal of medicine.

[27]  G. Lauss,et al.  Biobank governance in the post-genomic age. , 2010, Personalized medicine.

[28]  Hans Eiberg,et al.  Blue eye color in humans may be caused by a perfectly associated founder mutation in a regulatory element located within the HERC2 gene inhibiting OCA2 expression , 2008, Human Genetics.

[29]  K. Zatloukal,et al.  Biobank Governance: Trends and Perspectives , 2007, Pathobiology.

[30]  M. Gwinn,et al.  The Access Principle: The Case for Open Access to Research and Scholarship , 2006, Emerging Infectious Diseases.

[31]  Anne Cambon-Thomsen,et al.  The social and ethical issues of post-genomic human biobanks , 2004, Nature Reviews Genetics.

[32]  Clifford A. Lynch,et al.  Institutional Repositories: Essential Infrastructure For Scholarship In The Digital Age , 2003 .

[33]  L. Liu The contribution of library collections to prestige of academic programs of universities: a quantitative analysis , 2001 .

[34]  Y. Gingras,et al.  The place of universities in the system of knowledge production , 2000 .

[35]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[36]  N. Heisterkamp,et al.  Evidence that the phl gene encodes a 160,000-dalton phosphoprotein with associated kinase activity. , 1987, Molecular and cellular biology.

[37]  J. Schumm,et al.  Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. , 1985, Science.

[38]  H. Eiberg,et al.  Linkage relationships of paraoxonase (PON) with other markers: indication of PON‐cystic fibrosis synteny , 1985, Clinical genetics.

[39]  J. Rowley A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[40]  C. Waller Imatinib mesylate. , 2014, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[41]  K. Hoeyer The Emergence of an Entitlement Framework for Stored Tissue - Elements and Implications of an Escalating Conflict in Sweden , 2004 .

[42]  Loet Leydesdorff,et al.  Universities and the global knowledge economy: A triple helix of university-industry-government relations (2nd edition) , 2001 .

[43]  Peter J. Scambler,et al.  Localization of cystic fibrosis locus to human chromosome 7cen–q22 , 1985, Nature.

[44]  P. Nowell,et al.  A minute chromosome in human chronic granulocytic leukemia , 1960 .

[45]  L. Tsui,et al.  Cystic Fibrosis Locus Defined by a Genetically Linked Polymorphic Dna Marker Author(s): Lap , 2022 .